ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MAP0004
Drug: Inhaler Placebo
Drug: Moxifloxacin
Drug: Placebo Capsule

First Posted Date: 2010-08-31

Last Posted Date: 2014-01-09

Lead Sponsor: Allergan

Target Recruit Count: 54

Registration Number: NCT01191723

Locations: 🇺🇸
Cetero Research, Fargo, North Dakota, United States

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines

Phase 3

Completed

Conditions: Crow's Feet Lines
Lateral Canthus Rhytides

Interventions: Drug: normal saline
Biological: onabotulinumtoxinA

First Posted Date: 2010-08-27

Last Posted Date: 2019-05-07

Lead Sponsor: Allergan

Target Recruit Count: 446

Registration Number: NCT01189747

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Phase 3

Completed

Conditions: Facial Rhytides
Crow's Feet Lines
Glabellar Lines

Interventions: Biological: onabotulinumtoxinA 44 U
Biological: onabotulinumtoxinA 24 U
Drug: normal saline

First Posted Date: 2010-08-27

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 917

Registration Number: NCT01189760

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Phase 1

Completed

Conditions: Alopecia
Alopecia, Androgenetic
Baldness

Interventions: Drug: bimatoprost Formulation A
Drug: bimatoprost Formulation B
Drug: bimatoprost Formulation C

First Posted Date: 2010-08-26

Last Posted Date: 2013-08-30

Lead Sponsor: Allergan

Target Recruit Count: 42

Registration Number: NCT01189279

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: trospium chloride
Drug: oxybutynin IR
Drug: oxybutynin IR placebo

First Posted Date: 2010-08-10

Last Posted Date: 2016-02-26

Lead Sponsor: Allergan

Target Recruit Count: 20

Registration Number: NCT01178827

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: bimatoprost /timolol formulation A fixed combination ophthalmic solution
Drug: bimatoprost/timolol fixed combination ophthalmic solution

First Posted Date: 2010-08-06

Last Posted Date: 2013-03-29

Lead Sponsor: Allergan

Target Recruit Count: 561

Registration Number: NCT01177098

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution
Drug: bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops

First Posted Date: 2010-07-27

Last Posted Date: 2019-04-24

Lead Sponsor: Allergan

Target Recruit Count: 121

Registration Number: NCT01170884

Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye

Completed

Conditions: Dry Eye

Interventions: Procedure: Cataract Surgery and Limbal relaxing incision

First Posted Date: 2010-07-14

Last Posted Date: 2012-07-26

Lead Sponsor: Allergan

Target Recruit Count: 32

Registration Number: NCT01161771

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Phase 1

Completed

Conditions: Ocular Hypertension
Open-Angle Glaucoma

Interventions: Drug: bimatoprost 20 µg generation 2
Drug: bimatoprost 6 µg generation 2
Drug: bimatoprost 15 µg generation 2
Drug: bimatoprost 10 µg generation 2
Drug: bimatoprost 15 µg generation 1
Drug: bimatoprost 10 µg generation 1
Drug: bimatoprost 0.03%

First Posted Date: 2010-07-07

Last Posted Date: 2020-03-30

Lead Sponsor: Allergan

Target Recruit Count: 109

Registration Number: NCT01157364

Locations: 🇺🇸
Moyes Eye Center, Kansas City, Missouri, United States
🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸
The Eye Associates of Manatee, Bradenton, Florida, United States

and more 54 locations

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

Phase 2

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: AGN-214868
Drug: AGN-214868 placebo

First Posted Date: 2010-07-07

Last Posted Date: 2014-03-19

Lead Sponsor: Allergan

Target Recruit Count: 160

Registration Number: NCT01157377

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy